P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)

P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)

Bibliographic Details
Main Authors:	L. H. Sehn, K. Hübel, S. Luminari, A. Salar, B. E. Wahlin, A. K. Gopal, C. Bonnet, S. Paneesha, M. Trneny, H. Mashegu, C. Lihou, D. Li, C. W. Scholz
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000847280.69256.81

Similar Items

Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma
by: James L. Rubenstein, et al.
Published: (2018-07-01)

The Efficacy and Safety of Lenalidomide plus Rituximab in an Orbital Relapse of Diffuse Large B-Cell Lymphoma
by: R. Palmieri, et al.
Published: (2019-01-01)

PB2266: TRIAL IN PROGRESS: PHASE 3 TRIAL OF ODRONEXTAMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA (OLYMPIA-5)
by: Umberto Vitolo, et al.
Published: (2023-08-01)

P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
by: L. Nastoupil, et al.
Published: (2022-06-01)

Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma
by: Christian Winther Eskelund, et al.
Published: (2018-11-01)

P1163: ZANUBRUTINIB PLUS RITUXIMAB AND LENALIDOMIDE (ZR2) FOR RELAPSED AND REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
by: Xiyuan Zhang, et al.
Published: (2023-08-01)

Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma
by: Maria Patra-Kneuer, et al.
Published: (2023-07-01)

Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab
by: Pier Luigi Zinzani, et al.
Published: (2016-09-01)

PB2276: MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA
by: Antonio Salar Silvestre, et al.
Published: (2023-08-01)

Lenalidomide, rituximab, and methotrexate are effective in newly diagnosed primary central nervous system lymphoma
by: Xianggui Yuan, et al.
Published: (2024-02-01)

Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experience
by: Giulio Cassanello, et al.
Published: (2024-09-01)

Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma
by: Nathan H. Fowler, et al.
Published: (2015-11-01)

Pityriasis lichenoides chronica in a patient on tafasitamab and lenalidomide therapy for diffuse large B-cell lymphoma
by: Katie Roster, MS, et al.
Published: (2023-10-01)

Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma
by: Johannes Duell, et al.
Published: (2021-08-01)

Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma
by: Johannes Duell, et al.
Published: (2021-07-01)

PB2144: PEARL: A STUDY TO ASSESS THE EFFICACY AND SAFETY OF PENPULIMAB PLUS LENALIDOMIDE, RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
by: X. Wei, et al.
Published: (2022-06-01)

Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation
by: Zachary D. Epstein-Peterson, et al.
Published: (2023-08-01)

S222: EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS
by: Anna Sureda, et al.
Published: (2023-08-01)

Successful Treatment of Concomitant Pleural Mucosa-Associated Lymphoid Tissue Lymphoma and Monoclonal Gammopathy of Undetermined Significance with Lenalidomide, Rituximab, and Dexamethasone
by: Yoshiki Uemura, et al.
Published: (2022-01-01)

Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi
by: Francesco Zaja, et al.
Published: (2017-05-01)

Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi
by: Annalisa Chiappella, et al.
Published: (2013-11-01)

The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
by: Julio Delgado, et al.
Published: (2021-12-01)

Maintenance regimen of GM‐CSF with rituximab and lenalidomide improves survival in high‐risk B‐cell lymphoma by modulating natural killer cells
by: Shunrong Sun, et al.
Published: (2023-06-01)

Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial
by: Changhee Park, et al.
Published: (2024-03-01)

HHV8‐unrelated primary effusion lymphoma in a patient with HBV‐related liver cirrhosis: A case successfully treated with rituximab and lenalidomide
by: Peng‐Jun Liao, et al.
Published: (2023-06-01)

Lenalidomide in Diffuse Large B-Cell Lymphomas
by: Annalisa Chiappella, et al.
Published: (2012-01-01)

Lenalidomide in Diffuse Large B-Cell Lymphoma
by: Catherine Thieblemont, et al.
Published: (2012-01-01)

A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL
by: Chaitra Ujjani, et al.
Published: (2018-04-01)

Lenalidomide can be safely combined with chlorambucil and rituximab in older patients with chronic lymphocytic leukemia
by: Candida Vitale, et al.
Published: (2019-01-01)

INVESTIGATION OF THE MOLECULAR BASIS OF LENALIDOMIDE TREATMENT IN LYMPHOMA CELL LINES
by: Ballabio, E, et al.
Published: (2010)

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
by: Meletios A. Dimopoulos, et al.
Published: (2018-12-01)

<i>Erratum</i> to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation
by: Zachary D. Epstein-Peterson, et al.
Published: (2024-08-01)

A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma
by: Robin Noel, et al.
Published: (2023-12-01)

A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA
by: Laurie H. Sehn, et al.
Published: (2020-06-01)

Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study
by: Christopher R. Flowers, et al.
Published: (2023-09-01)

Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin’s Lymphomas
by: Marco Gunnellini, et al.
Published: (2012-01-01)

Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi
by: Stefano Sacchi, et al.
Published: (2016-05-01)

Rituximab, lenalidomide and BTK inhibitor as frontline treatment for elderly or unfit patients with diffuse large B-cell lymphoma: a real-world analysis of single center
by: Yanan Zhu, et al.
Published: (2022-09-01)

Effect and Safety of Orelabrutinib and Lenalidomide Plus R-mini CDOP in Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma
by: Ying Shang, et al.
Published: (2023-12-01)

P1113: COMPARATIVE EFFICACY OF ZANUBRUTINIB (ZANU) VERSUS RITUXIMAB (RTX) IN RELAPSED MARGINAL ZONE LYMPHOMA (MZL): MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC)
by: Catherine Thieblemont, et al.
Published: (2023-08-01)